Screener
Supernus Pharmaceuticals SUPN Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Goodwill | 120,668 | 124,882 |
| Deferred income tax assets, net | 30,820 | 38,351 |
| Other assets | 56,453 | 63,796 |
| Total assets | $1,500,725 | $1,452,648 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $101,244 | $107,800 |
| Accrued product returns and rebates | 189,720 | 161,097 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total assets?
- Supernus Pharmaceuticals (SUPN) reported total assets of $1.5B in Q1 2026.
- How has Supernus Pharmaceuticals's total assets changed year-over-year?
- Supernus Pharmaceuticals's total assets increased by 11.4% year-over-year, from $1.35B to $1.5B.
- What is the long-term trend for Supernus Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total assets has grown at a -0.7% compound annual growth rate (CAGR), from $1.5B to $1.45B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Supernus Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude